CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation HZ Qui, AT Hagymasi, S Bandyopadhyay, MC St Rose, ... The Journal of Immunology 187 (7), 3555-3564, 2011 | 182 | 2011 |
Glycoprotein 96 can chaperone both MHC class I-and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function ADH Doody, JT Kovalchin, MA Mihalyo, AT Hagymasi, CG Drake, ... The Journal of immunology 172 (10), 6087-6092, 2004 | 177 | 2004 |
Endocannabinoid system acts as a regulator of immune homeostasis in the gut N Acharya, S Penukonda, T Shcheglova, AT Hagymasi, S Basu, ... Proceedings of the National Academy of Sciences 114 (19), 5005-5010, 2017 | 151 | 2017 |
A novel sphingomyelinase‐like enzyme in Ixodes scapularis tick saliva drives host CD4+ T cells to express IL‐4 FJ ALARCON‐CHAIDEZ, VD Boppana, AT Hagymasi, AJ Adler, SK Wikel Parasite immunology 31 (4), 210-219, 2009 | 43 | 2009 |
CD134/CD137 dual costimulation‐elicited IFN‐γ maximizes effector T‐cell function but limits Treg expansion MC St. Rose, RA Taylor, S Bandyopadhyay, HZ Qui, AT Hagymasi, ... Immunology and cell biology 91 (2), 173-183, 2013 | 41 | 2013 |
Dendritic cells program non‐immunogenic prostate‐specific T cell responses beginning at early stages of prostate tumorigenesis MA Mihalyo, AT Hagymasi, AM Slaiby, EE Nevius, AJ Adler The Prostate 67 (5), 536-546, 2007 | 33 | 2007 |
Self-antigen prevents CD8 T cell effector differentiation by CD134 and CD137 dual costimulation S Bandyopadhyay, M Long, HZ Qui, AT Hagymasi, AM Slaiby, ... The Journal of Immunology 181 (11), 7728-7737, 2008 | 30 | 2008 |
An unbiased approach to defining bona fide cancer neoepitopes that elicit immune-mediated cancer rejection CA Brennick, MM George, MM Moussa, AT Hagymasi, S Al Seesi, ... The Journal of clinical investigation 131 (3), 2021 | 28 | 2021 |
T-bet down-modulation in tolerized Th1 effector CD4 cells confers a TCR-distal signaling defect that selectively impairs IFN-γ expression M Long, AM Slaiby, AT Hagymasi, MA Mihalyo, AC Lichtler, SL Reiner, ... The Journal of Immunology 176 (2), 1036-1045, 2006 | 24 | 2006 |
Steady state dendritic cells present parenchymal self-antigen and contribute to, but are not essential for, tolerization of naive and Th1 effector CD4 cells AT Hagymasi, AM Slaiby, MA Mihalyo, HZ Qui, DJ Zammit, L Lefrancois, ... The Journal of Immunology 179 (3), 1524-1531, 2007 | 23 | 2007 |
Heat‐Shock Proteins AT Hagymasi, JP Dempsey, PK Srivastava Current protocols 2 (11), e592, 2022 | 21 | 2022 |
Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope H Ebrahimi-Nik, M Moussa, RP Englander, S Singhaviranon, J Michaux, ... Nature Communications 12 (1), 6423, 2021 | 20 | 2021 |
Histone acetylation at the Ifng promoter in tolerized CD4 cells is associated with increased IFN-γ expression during subsequent immunization to the same antigen M Long, AM Slaiby, S Wu, AT Hagymasi, MA Mihalyo, S Bandyopadhyay, ... The Journal of Immunology 179 (9), 5669-5677, 2007 | 13 | 2007 |
An immunotherapeutic CD137 agonist releases eomesodermin from ThPOK repression in CD4 T cells P Mittal, R Abblett, JM Ryan, AT Hagymasi, A Agyekum-Yamoah, ... The Journal of Immunology 200 (4), 1513-1526, 2018 | 10 | 2018 |
The E3 ubiquitin ligase Cbl-b regulates expansion but not functional activity of self-reactive CD4 T cells MC St Rose, HZ Qui, S Bandyopadhyay, MA Mihalyo, AT Hagymasi, ... The Journal of Immunology 183 (8), 4975-4983, 2009 | 8 | 2009 |
GRK2 enforces androgen receptor dependence in the prostate and prostate tumors AJ Adler, P Mittal, AT Hagymasi, A Menoret, C Shen, F Agliano, KT Wright, ... Oncogene 39 (11), 2424-2436, 2020 | 4 | 2020 |
Low avidity CD8+ T cells are less exhausted than their high avidity counterparts and provide superior anti-tumor immunity S Singhaviranon, J Dempsey, A Hagymasi, I Mandoiu, PK Srivastava The Journal of Immunology 210 (1_Supplement), 171.10-171.10, 2023 | 1 | 2023 |
Geneo: a bioinformatics toolbox for genomics-guided neoepitope prediction S Al Seesi, A Al-Okaily, TV Shcheglova, E Sherafat, FH Alqahtani, ... Journal of Computational Biology 30 (4), 538-551, 2023 | 1 | 2023 |
Gp96 can chaperone both MHC class I and class II-restricted epitopes for in vivo presentation, but selectively primes CD8 (+) T-cell effector function ADH Doody, JT Kovalchin, MA Mihalyo, AT Hagymasi, CG Drake, ... Immunology 114 (1), 141-141, 2005 | 1 | 2005 |
Low avidity T cells drive endogenous tumor immunity in mice and humans P Srivastava, S Singhaviranon, J Dempsey, A Hagymasi, I Mandoiu | | 2024 |